Aquestive Therapeutics, Inc.

NasdaqGM:AQST Rapporto sulle azioni

Cap. di mercato: US$411.2m

Aquestive Therapeutics Gestione

Gestione criteri di controllo 2/4

Aquestive Therapeutics Il CEO è Dan Barber, nominato in May2022, e ha un mandato di 2.5 anni. la retribuzione annua totale è $ 2.50M, composta da 24% di stipendio e 76% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.52% delle azioni della società, per un valore di $ 6.24M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 2.2 anni.

Informazioni chiave

Dan Barber

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO24.0%
Mandato del CEO2.5yrs
Proprietà del CEO1.5%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 05

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Aquestive Therapeutics: A First Take

Aug 29

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan Barber rispetto agli utili di Aquestive Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$899kUS$300k

-US$14m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 2.50M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.18M ).

Compensazione vs guadagni: La retribuzione di Dan è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Dan Barber (48 yo)

2.5yrs

Mandato

US$2,496,141

Compensazione

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 6.2m
A. Toth
Chief Financial Officer3.9yrsUS$1.12m0.43%
$ 1.8m
Lori Braender
General Counsel6.2yrsUS$1.19m0.52%
$ 2.2m
Cassie Jung
Chief Operating Officer2yrsNessun dato0.25%
$ 1.0m
Alexander Schobel
Chief Innovation & Technology Officer9.9yrsUS$810.02k1.08%
$ 4.4m
Stephen Wargacki
Chief Science Officerno dataNessun dato0.28%
$ 1.2m
Sherry Korczynski
Senior Vice President of Sales & Marketingless than a yearNessun dato0.027%
$ 112.8k
Peter Boyd
Senior Vice President of Information Technology & Human Resources1.7yrsNessun dato0.26%
$ 1.1m
Gary Slatko
Chief Medical Officerno dataNessun datoNessun dato
Carl Kraus
Chief Medical Officer1.4yrsNessun dato0.28%
$ 1.1m
Robert Arnold
VP of Financeno dataNessun datoNessun dato

2.3yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di AQST è considerato esperto (durata media dell'incarico 2.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 6.2m
Timothy Morris
Independent Director2.3yrsUS$145.23k0%
$ 0
Gregory Brown
Independent Chairman of the Board17.7yrsUS$150.77k0.082%
$ 338.6k
Julie Krop
Independent Director3.8yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board20.8yrsUS$137.23k0.11%
$ 448.7k
Marco Taglietti
Independent Director3.8yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato
Ruchi Gupta
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato
David Bernstein
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato
David Fleischer
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato
Matthew Greenhawt
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato
Jay Lieberman
Member of Scientific Advisory Board2.2yrsNessun datoNessun dato

2.2yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AQST non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.